Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors

被引:12
|
作者
Li, Gaoquan [1 ]
Tao, Zhi-Fu [1 ]
Tong, Yunsong [1 ]
Przytulinska, Magdalena K. [1 ]
Kovar, Peter [1 ]
Merta, Philip [1 ]
Chen, Zehan [1 ]
Zhang, Haiying [1 ]
Sowin, Thomas [1 ]
Rosenberg, Saul H. [1 ]
Lin, Nan-Horng [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA
关键词
macrocyclic urea; Chk1; inhibitor;
D O I
10.1016/j.bmcl.2007.09.088
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A variety of macrocyclic urea compounds were prepared as potent Chk1 inhibitors by modifying the C5 position of the benzene ring of the macrocyclic urea with ether moieties, aliphatic carbon chains, amide and halides. Enzymatic activity less than 20 nM was observed in 29 of 40 compounds. Compounds 14, 46d, and 48j provided the best overall results in the cellular assays as they abrogated doxorubicin-induced cell cycle arrest (IC50 = 3.31, 3.08, and 3.13 mu M) and enhanced doxorubicin cytotoxicity (IC50 = 0.54, 1.27, and 0.96 mu M) while displaying no single agent activity, respectively. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6499 / 6504
页数:6
相关论文
共 50 条
  • [31] The Efficacy of CHK1 Inhibitors Is Not Altered by Hypoxia, but Is Enhanced after Reoxygenation
    Hasvold, Grete
    Nahse-Kumpf, Viola
    Tkacz-Stachowska, Kinga
    Rofstad, Einar K.
    Syljuasen, Randi G.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) : 705 - 716
  • [32] Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates
    Dudkin, Vadim Y.
    Rickert, Keith
    Kreatsoulas, Constantine
    Wang, Cheng
    Arrington, Kenneth L.
    Fraley, Mark E.
    Hartman, George D.
    Yan, Yowei
    Ikuta, Mari
    Stirdivant, Steven M.
    Drakas, Robert A.
    Walsh, Eileen S.
    Hamilton, Kelly
    Buser, Carolyn A.
    Lobell, Robert B.
    Sepp-Lorenzino, Laura
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (07) : 2609 - 2612
  • [33] Novel 5-azaindolocarbazoles as cytotoxic agents and Chk1 inhibitors
    Lefoix, Myriam
    Coudert, Gerard
    Routier, Sylvain
    Pfeiffer, Bruno
    Caignard, Daniel-Henri
    Hickman, John
    Pierre, Alain
    Golsteyn, Roy M.
    Leonce, Stephane
    Bossard, Celine
    Merour, Jean-Yves
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (09) : 5303 - 5321
  • [34] Targeting regulators of Chk1 to enhance cytotoxic efficacy of HDAC inhibitors
    Kreahling, Jenny M.
    Gemmer, Jennifer Y.
    Ma, Yihong
    Cress, Douglas
    Johnson, Jackie
    Chellappan, Srikumar P.
    Altiok, Soner
    CANCER RESEARCH, 2011, 71
  • [35] Less is more: subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors in vitro and in vivo
    Oo, Z. U.
    Proctor, M.
    Stevenson, A.
    Nazareth, D.
    Haass, N.
    Larsen, J.
    Gabrielli, B.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E30 - E31
  • [36] The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia
    di Rora, Andrea Ghelli Luserna
    Iacobucci, Ilaria
    Imbrogno, Enrica
    Derenzini, Enrico
    Ferrari, Anna
    Robustelli, Valentina
    Guadagnuolo, Viviana
    Papayannidis, Cristina
    Abbenante, Maria Chiara
    Grilli, Sandro
    Martinelli, Giovanni
    CANCER RESEARCH, 2016, 76
  • [37] Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity
    M Walker
    E J Black
    V Oehler
    D A Gillespie
    M T Scott
    Oncogene, 2009, 28 : 2314 - 2323
  • [38] Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity
    Walker, M.
    Black, E. J.
    Oehler, V.
    Gillespie, D. A.
    Scott, M. T.
    ONCOGENE, 2009, 28 (24) : 2314 - 2323
  • [39] Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis
    Lavrard, Hubert
    Rodriguez, Frederic
    Delfourne, Evelyne
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (17) : 4961 - 4967
  • [40] Inhibition of Protein Synthesis Induced by CHK1 Inhibitors Discriminates Sensitive from Resistant Cancer Cells
    Hinds, John W.
    Ditano, Jennifer P.
    Eastman, Alan
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2021, 4 (04) : 1449 - 1461